A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

NCT02978482 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignancy

Interventions

DRUG: durvalumab
DRUG: tremelimumab + durvalumab

Sponsor

AstraZeneca